|
Inverseon Focuses on Mucous and Smoking Cessation
MarketWatch (press release) 12, 2012 /PRNewswire via COMTEX/ — Inverseon, Inc., a pharmaceutical company developing drug therapies for the treatment of pulmonary disorders, announced that while it anticipates that its asthma program will advance with non-dilutive grants, … |
View full post on asthma – Google News